Z. Raykov

发表

TLR-9 Contributes to the Antiviral Innate Immune Sensing of Rodent Parvoviruses MVMp and H-1PV by Normal Human Immune Cells

T. Giese, N. Giese, R. Zawatzky, 2013, PloS one.

Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases

M. Aprahamian, J. Rommelaere, G. Balboni, 2004, International journal of cancer.

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

T. Giese, N. Giese, M. Aprahamian, 2010, Cancer biology & therapy.

Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

A. Ho, M. Aprahamian, J. Rommelaere, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas

M. Schnölzer, M. Aprahamian, A. Marchini, 2013, EMBO molecular medicine.

Parvoviruses: The Friendly Anticancer Immunomodulator

J. Rommelaere, A. Angelova, Z. Raykov, 2013 .

Oncolytic parvoviruses as cancer therapeutics.

J. Rommelaere, K. Geletneky, L. Daeffler, 2010, Cytokine & growth factor reviews.

Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity

M. Aprahamian, B. Leuchs, J. Rommelaere, 2008, International journal of cancer.

Oncolytic Parvoviruses as Tools for Cancer Gene Therapy

M. Aprahamian, J. Rommelaere, A. Galabov, 2004 .

Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

M. Aprahamian, J. Rommelaere, U. Koch, 2007, Oncology reports.

B1 Lymphocytes and Myeloid Dendritic Cells in Lymphoid Organs Are Preferential Extratumoral Sites of Parvovirus Minute Virus of Mice Prototype Strain Expression

T. Giese, N. Giese, J. Rommelaere, 2005, Journal of Virology.

Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer

T. Giese, A. Heller, J. Werner, 2014, Journal of Virology.

Parvoviruses-tools to fine-tune anticancer immune responses

J. Rommelaere, Z. Raykov, S. Grekova, 2012, Oncoimmunology.

Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV

N. Giese, A. Hajri, M. Aprahamian, 2009, Clinical Cancer Research.

Pancreatic Cancer Cell Lines Can Induce Prostaglandin E2 Production from Human Blood Mononuclear Cells

L. Daeffler, A. Angelova, Z. Raykov, 2011, Journal of oncology.

Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.

J. Rommelaere, A. Angelova, A. Galabov, 2009, Acta virologica.

Antitumour effects of combined radio- and parvovirotherapy in n-Ras-positive tumour cells

J. Rommelaere, A. Angelova, A. Galabov, 2007 .

Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer

T. Giese, A. Heller, N. Giese, 2011, Cancer biology & therapy.

Genomic CpG enrichment of oncolytic parvoviruses as a potent anticancer vaccination strategy for the treatment of pancreatic adenocarcinoma

T. Giese, A. Heller, N. Giese, 2014 .

Structural imaging of the pancreas in rat using micro-CT: application to a non-invasive longitudinal evaluation of pancreatic ductal carcinoma monitoring

J. Marescaux, D. Mutter, M. Aprahamian, 2013 .

Improvement of Gemcitabine-BasedTherapy of Pancreatic Carcinoma byMeans of Oncolytic Parvovirus H-1 PV

N. Giese, M. Aprahamian, A. Angelova, 2009 .

Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer

T. Giese, A. Heller, J. Werner, 2014, Journal of Virology.

Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection

R. Zawatzky, J. Rommelaere, U. Koch, 2012, Cancer Gene Therapy.